<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02083107</url>
  </required_header>
  <id_info>
    <org_study_id>9021344</org_study_id>
    <nct_id>NCT02083107</nct_id>
  </id_info>
  <brief_title>Comparison Between Rectal &amp; Sublingual Misoprostol Before Caesarian Section To Reduce Intra &amp; Post-Operative Blood Loss</brief_title>
  <official_title>COMPARISON BETWEEN RECTAL &amp; SUBLINGUAL MISOPROSTOL BEFORE CAESARIAN SECTION TO REDUCE INTRA &amp; POST-OPERATIVE BLOOD LOSS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the work is to evaluate &amp; compare the effectiveness of rectally administered PGE1
      synthetic analogue (misoprostol) 400 microgram versus sublingually administered misoprostol
      before caesarean section to decrease blood loss during and after the operation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraoperative Blood Loss</measure>
    <time_frame>from start of cesarean section till the end of operation (average one hour)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Need for Extra Ecbolics (Oxytocin).</measure>
    <time_frame>from start of cesarean section till the end of operation (average one hour)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>APGAR Score</measure>
    <time_frame>1minute and 5 minutes from delivery of the fetus</time_frame>
    <description>The Apgar score is the first test given to a newborn, it is referred to as an acronym for: Appearance, Pulse, Grimace, Activity, and Respiration. Scores obtainable are between 10 and 0, with 10 being the highest possible score. Pulse: above 100 beats per minute (2), below 100 beats per minute (1), absent (0). Respiration: Normal rate and effort, good cry (2), Slow or irregular,weak cry (1), absent (0). Grimace: Pulls away, sneezes, coughs, or cries with stimulation (2), Facial movement only (1), absent (0). Activity: Active, spontaneous movement (2), Arms and legs flexed with little movement (1), absent (0). Appearance: Normal color (2), Normal color (but hands and feet are bluish) (1), Bluish-gray or pale all over (0).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Resume Bowel Habits</measure>
    <time_frame>average 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for Extra Analgesics</measure>
    <time_frame>average 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for Postoperative Blood Transfusion</measure>
    <time_frame>average 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Wound Sepsis</measure>
    <time_frame>upto one week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Effects</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in Hemoglobin Concentration</measure>
    <time_frame>24 hours postoperative from baseline hemoglobin</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in Hematocrite Value</measure>
    <time_frame>24 hours postoperative from baseline hematocrite value</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">636</enrollment>
  <condition>Postpartum Hemorrhage</condition>
  <arm_group>
    <arm_group_label>sublingual misoprostol &amp; rectal placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>will receive 400 microgram of misoprostol (Sigma) sublingual &quot;2 tablets&quot; and rectal placebo&quot;2 tablets&quot;.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rectal &amp; sublingual placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>will receive rectal placebo&quot;2 tablets&quot; and sublingual placebo&quot;2 tablets&quot;.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rectal misoprostol &amp; sublingual placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>will receive 400 microgram of misoprostol (Sigma) rectal &quot;2 tablets&quot; and sublingual placebo&quot;2 tablets&quot;.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <description>Comparison of different routes of administration of 400 micro gram misoprostol</description>
    <arm_group_label>sublingual misoprostol &amp; rectal placebo</arm_group_label>
    <arm_group_label>rectal misoprostol &amp; sublingual placebo</arm_group_label>
    <other_name>Misotac</other_name>
    <other_name>Cytotec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>rectal &amp; sublingual placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients booked for elective cesarean section.

          2. Singleton pregnancies. 3- Full term pregnancies (GA 37-42 weeks). 4- Patients with
             only previous one cesarian section

        Exclusion Criteria:

          1. Primigravida.

          2. Blood dyscrasias.

          3. Large fibroids.

          4. Multiple pregnancies.

          5. Overdistended uterus eg. Hydramnios.

          6. Pre-eclampsia.

          7. Marked maternal anemia (Preoperative hemoglobin &lt; 9 gm/dl).

          8. Previous history of PPH.

          9. Contraindications to prostaglandin therapy (e.g. history of severe bronchial asthma or
             allergy to misoprostol.

         10. Placenta previa.

         11. Contraindication to spinal anesthesia.

         12. Previous myomectomy.

         13. Previous two or more C.S.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed S. Sweed, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ain Shams University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mourad M. El-Said, Professor</last_name>
    <role>Study Director</role>
    <affiliation>AinShams University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amgad E. Abou-Gamrah, Ass.Prof.</last_name>
    <role>Study Director</role>
    <affiliation>AinShams university</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Haitham El-Sabe, MD</last_name>
    <role>Study Director</role>
    <affiliation>AinShams University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohamed M. AbdEl-Hamid, Registrar</last_name>
    <role>Principal Investigator</role>
    <affiliation>AinShams University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ain Shams University Maternity Hospital</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2014</study_first_submitted>
  <study_first_submitted_qc>March 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2014</study_first_posted>
  <results_first_submitted>April 24, 2014</results_first_submitted>
  <results_first_submitted_qc>May 26, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 27, 2014</results_first_posted>
  <last_update_submitted>November 22, 2015</last_update_submitted>
  <last_update_submitted_qc>November 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Mohamed S Sweed, MD</investigator_full_name>
    <investigator_title>Mohamed S. Sweed, Lecturer of Obstetrics &amp;Gynecology, Ain Shams University</investigator_title>
  </responsible_party>
  <keyword>Postpartum hemorrhage</keyword>
  <keyword>Intrapartum blood loss</keyword>
  <keyword>Misoprostol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Postpartum Hemorrhage</mesh_term>
    <mesh_term>Postoperative Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sublingual Misoprostol &amp; Rectal Placebo</title>
          <description>will receive 400 microgram of misoprostol (Sigma) sublingual &quot;2 tablets&quot; and rectal placebo&quot;2 tablets&quot;.
Misoprostol: Comparison of different routes of administration of 400 micro gram misoprostol</description>
        </group>
        <group group_id="P2">
          <title>Rectal &amp; Sublingual Placebo</title>
          <description>will receive rectal placebo&quot;2 tablets” and sublingual placebo&quot;2 tablets”.</description>
        </group>
        <group group_id="P3">
          <title>Rectal Misoprostol &amp; Sublingual Placebo</title>
          <description>will receive 400 microgram of misoprostol (Sigma) rectal &quot;2 tablets&quot; and sublingual placebo&quot;2 tablets&quot;.
Misoprostol: Comparison of different routes of administration of 400 micro gram misoprostol</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="212">212 women received 2 tablets of Misotac® sublingually and 2 placebo tablets rectally.</participants>
                <participants group_id="P2" count="212">212 women received 2 tablets of placebo sublingually and 2 placebo tablets rectally.</participants>
                <participants group_id="P3" count="212">212 women received 2 tablets of Misotac® rectally and 2 placebo tablets sublingually.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="212">212 women received 2 tablets of Misotac® sublingually and 2 placebo tablets rectally.</participants>
                <participants group_id="P2" count="212">212 women received 2 tablets of placebo sublingually and 2 placebo tablets rectally.</participants>
                <participants group_id="P3" count="212">212 women received 2 tablets of Misotac® rectally and 2 placebo tablets sublingually.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sublingual Misoprostol &amp; Rectal Placebo</title>
          <description>will receive 400 microgram of misoprostol (Sigma) sublingual &quot;2 tablets&quot; and rectal placebo&quot;2 tablets&quot;.
Misoprostol: Comparison of different routes of administration of 400 micro gram misoprostol</description>
        </group>
        <group group_id="B2">
          <title>Rectal &amp; Sublingual Placebo</title>
          <description>will receive rectal placebo&quot;2 tablets” and sublingual placebo&quot;2 tablets”.</description>
        </group>
        <group group_id="B3">
          <title>Rectal Misoprostol &amp; Sublingual Placebo</title>
          <description>will receive 400 microgram of misoprostol (Sigma) rectal &quot;2 tablets&quot; and sublingual placebo&quot;2 tablets&quot;.
Misoprostol: Comparison of different routes of administration of 400 micro gram misoprostol</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="212"/>
            <count group_id="B2" value="212"/>
            <count group_id="B3" value="212"/>
            <count group_id="B4" value="636"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.9" spread="2.6"/>
                    <measurement group_id="B2" value="26.4" spread="2.7"/>
                    <measurement group_id="B3" value="26.5" spread="2.5"/>
                    <measurement group_id="B4" value="26.6" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="212"/>
                    <measurement group_id="B2" value="212"/>
                    <measurement group_id="B3" value="212"/>
                    <measurement group_id="B4" value="636"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>Kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.5" spread="1.7"/>
                    <measurement group_id="B2" value="27.6" spread="1.9"/>
                    <measurement group_id="B3" value="27.4" spread="1.7"/>
                    <measurement group_id="B4" value="27.5" spread="1.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Parity</title>
          <units>Births</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1" lower_limit="1" upper_limit="2"/>
                    <measurement group_id="B2" value="1" lower_limit="1" upper_limit="2"/>
                    <measurement group_id="B3" value="1" lower_limit="1" upper_limit="2"/>
                    <measurement group_id="B4" value="1" lower_limit="1" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gestational Age</title>
          <units>Weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.9" spread="1"/>
                    <measurement group_id="B2" value="38.9" spread="0.9"/>
                    <measurement group_id="B3" value="38.8" spread="0.9"/>
                    <measurement group_id="B4" value="38.8" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Intraoperative Blood Loss</title>
        <time_frame>from start of cesarean section till the end of operation (average one hour)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sublingual Misoprostol &amp; Rectal Placebo</title>
            <description>will receive 400 microgram of misoprostol (Sigma) sublingual &quot;2 tablets&quot; and rectal placebo&quot;2 tablets&quot;.
Misoprostol: Comparison of different routes of administration of 400 micro gram misoprostol</description>
          </group>
          <group group_id="O2">
            <title>Rectal &amp; Sublingual Placebo</title>
            <description>will receive rectal placebo&quot;2 tablets” and sublingual placebo&quot;2 tablets”.</description>
          </group>
          <group group_id="O3">
            <title>Rectal Misoprostol &amp; Sublingual Placebo</title>
            <description>will receive 400 microgram of misoprostol (Sigma) rectal &quot;2 tablets&quot; and sublingual placebo&quot;2 tablets&quot;.
Misoprostol: Comparison of different routes of administration of 400 micro gram misoprostol</description>
          </group>
        </group_list>
        <measure>
          <title>Intraoperative Blood Loss</title>
          <units>millilitres</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="357.8" spread="129.7"/>
                    <measurement group_id="O2" value="641.7" spread="135.7"/>
                    <measurement group_id="O3" value="457.5" spread="140.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Need for Extra Ecbolics (Oxytocin).</title>
        <time_frame>from start of cesarean section till the end of operation (average one hour)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sublingual Misoprostol &amp; Rectal Placebo</title>
            <description>will receive 400 microgram of misoprostol (Sigma) sublingual &quot;2 tablets&quot; and rectal placebo&quot;2 tablets&quot;.
Misoprostol: Comparison of different routes of administration of 400 micro gram misoprostol</description>
          </group>
          <group group_id="O2">
            <title>Rectal &amp; Sublingual Placebo</title>
            <description>will receive rectal placebo&quot;2 tablets” and sublingual placebo&quot;2 tablets”.</description>
          </group>
          <group group_id="O3">
            <title>Rectal Misoprostol &amp; Sublingual Placebo</title>
            <description>will receive 400 microgram of misoprostol (Sigma) rectal &quot;2 tablets&quot; and sublingual placebo&quot;2 tablets&quot;.
Misoprostol: Comparison of different routes of administration of 400 micro gram misoprostol</description>
          </group>
        </group_list>
        <measure>
          <title>Need for Extra Ecbolics (Oxytocin).</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="209"/>
                    <measurement group_id="O2" value="206"/>
                    <measurement group_id="O3" value="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Hemoglobin Concentration</title>
        <time_frame>24 hours postoperative from baseline hemoglobin</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sublingual Misoprostol &amp; Rectal Placebo</title>
            <description>will receive 400 microgram of misoprostol (Sigma) sublingual &quot;2 tablets&quot; and rectal placebo&quot;2 tablets&quot;.
Misoprostol: Comparison of different routes of administration of 400 micro gram misoprostol</description>
          </group>
          <group group_id="O2">
            <title>Rectal &amp; Sublingual Placebo</title>
            <description>will receive rectal placebo&quot;2 tablets” and sublingual placebo&quot;2 tablets”.</description>
          </group>
          <group group_id="O3">
            <title>Rectal Misoprostol &amp; Sublingual Placebo</title>
            <description>will receive 400 microgram of misoprostol (Sigma) rectal &quot;2 tablets&quot; and sublingual placebo&quot;2 tablets&quot;.
Misoprostol: Comparison of different routes of administration of 400 micro gram misoprostol</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hemoglobin Concentration</title>
          <units>gram/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.1"/>
                    <measurement group_id="O2" value="-0.9" spread="0.1"/>
                    <measurement group_id="O3" value="-0.4" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>APGAR Score</title>
        <description>The Apgar score is the first test given to a newborn, it is referred to as an acronym for: Appearance, Pulse, Grimace, Activity, and Respiration. Scores obtainable are between 10 and 0, with 10 being the highest possible score. Pulse: above 100 beats per minute (2), below 100 beats per minute (1), absent (0). Respiration: Normal rate and effort, good cry (2), Slow or irregular,weak cry (1), absent (0). Grimace: Pulls away, sneezes, coughs, or cries with stimulation (2), Facial movement only (1), absent (0). Activity: Active, spontaneous movement (2), Arms and legs flexed with little movement (1), absent (0). Appearance: Normal color (2), Normal color (but hands and feet are bluish) (1), Bluish-gray or pale all over (0).</description>
        <time_frame>1minute and 5 minutes from delivery of the fetus</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sublingual Misoprostol &amp; Rectal Placebo</title>
            <description>will receive 400 microgram of misoprostol (Sigma) sublingual &quot;2 tablets&quot; and rectal placebo&quot;2 tablets&quot;.
Misoprostol: Comparison of different routes of administration of 400 micro gram misoprostol</description>
          </group>
          <group group_id="O2">
            <title>Rectal &amp; Sublingual Placebo</title>
            <description>will receive rectal placebo&quot;2 tablets” and sublingual placebo&quot;2 tablets”.</description>
          </group>
          <group group_id="O3">
            <title>Rectal Misoprostol &amp; Sublingual Placebo</title>
            <description>will receive 400 microgram of misoprostol (Sigma) rectal &quot;2 tablets&quot; and sublingual placebo&quot;2 tablets&quot;.
Misoprostol: Comparison of different routes of administration of 400 micro gram misoprostol</description>
          </group>
        </group_list>
        <measure>
          <title>APGAR Score</title>
          <description>The Apgar score is the first test given to a newborn, it is referred to as an acronym for: Appearance, Pulse, Grimace, Activity, and Respiration. Scores obtainable are between 10 and 0, with 10 being the highest possible score. Pulse: above 100 beats per minute (2), below 100 beats per minute (1), absent (0). Respiration: Normal rate and effort, good cry (2), Slow or irregular,weak cry (1), absent (0). Grimace: Pulls away, sneezes, coughs, or cries with stimulation (2), Facial movement only (1), absent (0). Activity: Active, spontaneous movement (2), Arms and legs flexed with little movement (1), absent (0). Appearance: Normal color (2), Normal color (but hands and feet are bluish) (1), Bluish-gray or pale all over (0).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>APGAR 1 minute</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" spread="0.5"/>
                    <measurement group_id="O2" value="6.5" spread="0.5"/>
                    <measurement group_id="O3" value="6.5" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>APGAR 5 minute</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" spread="0.5"/>
                    <measurement group_id="O2" value="8.5" spread="0.5"/>
                    <measurement group_id="O3" value="8.5" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Resume Bowel Habits</title>
        <time_frame>average 24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sublingual Misoprostol &amp; Rectal Placebo</title>
            <description>will receive 400 microgram of misoprostol (Sigma) sublingual &quot;2 tablets&quot; and rectal placebo&quot;2 tablets&quot;.
Misoprostol: Comparison of different routes of administration of 400 micro gram misoprostol</description>
          </group>
          <group group_id="O2">
            <title>Rectal &amp; Sublingual Placebo</title>
            <description>will receive rectal placebo&quot;2 tablets” and sublingual placebo&quot;2 tablets”.</description>
          </group>
          <group group_id="O3">
            <title>Rectal Misoprostol &amp; Sublingual Placebo</title>
            <description>will receive 400 microgram of misoprostol (Sigma) rectal &quot;2 tablets&quot; and sublingual placebo&quot;2 tablets&quot;.
Misoprostol: Comparison of different routes of administration of 400 micro gram misoprostol</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Resume Bowel Habits</title>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.1" spread="3.1"/>
                    <measurement group_id="O2" value="14.7" spread="3.5"/>
                    <measurement group_id="O3" value="14.5" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Need for Extra Analgesics</title>
        <time_frame>average 24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sublingual Misoprostol &amp; Rectal Placebo</title>
            <description>will receive 400 microgram of misoprostol (Sigma) sublingual &quot;2 tablets&quot; and rectal placebo&quot;2 tablets&quot;.
Misoprostol: Comparison of different routes of administration of 400 micro gram misoprostol</description>
          </group>
          <group group_id="O2">
            <title>Rectal &amp; Sublingual Placebo</title>
            <description>will receive rectal placebo&quot;2 tablets” and sublingual placebo&quot;2 tablets”.</description>
          </group>
          <group group_id="O3">
            <title>Rectal Misoprostol &amp; Sublingual Placebo</title>
            <description>will receive 400 microgram of misoprostol (Sigma) rectal &quot;2 tablets&quot; and sublingual placebo&quot;2 tablets&quot;.
Misoprostol: Comparison of different routes of administration of 400 micro gram misoprostol</description>
          </group>
        </group_list>
        <measure>
          <title>Need for Extra Analgesics</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="62"/>
                    <measurement group_id="O3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Need for Postoperative Blood Transfusion</title>
        <time_frame>average 24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sublingual Misoprostol &amp; Rectal Placebo</title>
            <description>will receive 400 microgram of misoprostol (Sigma) sublingual &quot;2 tablets&quot; and rectal placebo&quot;2 tablets&quot;.
Misoprostol: Comparison of different routes of administration of 400 micro gram misoprostol</description>
          </group>
          <group group_id="O2">
            <title>Rectal &amp; Sublingual Placebo</title>
            <description>will receive rectal placebo&quot;2 tablets” and sublingual placebo&quot;2 tablets”.</description>
          </group>
          <group group_id="O3">
            <title>Rectal Misoprostol &amp; Sublingual Placebo</title>
            <description>will receive 400 microgram of misoprostol (Sigma) rectal &quot;2 tablets&quot; and sublingual placebo&quot;2 tablets&quot;.
Misoprostol: Comparison of different routes of administration of 400 micro gram misoprostol</description>
          </group>
        </group_list>
        <measure>
          <title>Need for Postoperative Blood Transfusion</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Wound Sepsis</title>
        <time_frame>upto one week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sublingual Misoprostol &amp; Rectal Placebo</title>
            <description>will receive 400 microgram of misoprostol (Sigma) sublingual &quot;2 tablets&quot; and rectal placebo&quot;2 tablets&quot;.
Misoprostol: Comparison of different routes of administration of 400 micro gram misoprostol</description>
          </group>
          <group group_id="O2">
            <title>Rectal &amp; Sublingual Placebo</title>
            <description>will receive rectal placebo&quot;2 tablets” and sublingual placebo&quot;2 tablets”.</description>
          </group>
          <group group_id="O3">
            <title>Rectal Misoprostol &amp; Sublingual Placebo</title>
            <description>will receive 400 microgram of misoprostol (Sigma) rectal &quot;2 tablets&quot; and sublingual placebo&quot;2 tablets&quot;.
Misoprostol: Comparison of different routes of administration of 400 micro gram misoprostol</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Wound Sepsis</title>
          <units>no. of cases experiencing wound sepsis</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Adverse Effects</title>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sublingual Misoprostol &amp; Rectal Placebo</title>
            <description>will receive 400 microgram of misoprostol (Sigma) sublingual &quot;2 tablets&quot; and rectal placebo&quot;2 tablets&quot;.
Misoprostol: Comparison of different routes of administration of 400 micro gram misoprostol</description>
          </group>
          <group group_id="O2">
            <title>Rectal &amp; Sublingual Placebo</title>
            <description>will receive rectal placebo&quot;2 tablets” and sublingual placebo&quot;2 tablets”.</description>
          </group>
          <group group_id="O3">
            <title>Rectal Misoprostol &amp; Sublingual Placebo</title>
            <description>will receive 400 microgram of misoprostol (Sigma) rectal &quot;2 tablets&quot; and sublingual placebo&quot;2 tablets&quot;.
Misoprostol: Comparison of different routes of administration of 400 micro gram misoprostol</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adverse Effects</title>
          <units>no. of cases experiencing side effects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Hematocrite Value</title>
        <time_frame>24 hours postoperative from baseline hematocrite value</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sublingual Misoprostol &amp; Rectal Placebo</title>
            <description>will receive 400 microgram of misoprostol (Sigma) sublingual &quot;2 tablets&quot; and rectal placebo&quot;2 tablets&quot;.
Misoprostol: Comparison of different routes of administration of 400 micro gram misoprostol</description>
          </group>
          <group group_id="O2">
            <title>Rectal &amp; Sublingual Placebo</title>
            <description>will receive rectal placebo&quot;2 tablets” and sublingual placebo&quot;2 tablets”.</description>
          </group>
          <group group_id="O3">
            <title>Rectal Misoprostol &amp; Sublingual Placebo</title>
            <description>will receive 400 microgram of misoprostol (Sigma) rectal &quot;2 tablets&quot; and sublingual placebo&quot;2 tablets&quot;.
Misoprostol: Comparison of different routes of administration of 400 micro gram misoprostol</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hematocrite Value</title>
          <units>Percentage Hematocrit</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.8"/>
                    <measurement group_id="O2" value="-1.6" spread="0.3"/>
                    <measurement group_id="O3" value="-0.1" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>starting intra-operative till one week postoperative (time of checking the wound)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sublingual Misoprostol &amp; Rectal Placebo</title>
          <description>will receive 400 microgram of misoprostol (Sigma) sublingual &quot;2 tablets&quot; and rectal placebo&quot;2 tablets&quot;.
Misoprostol: Comparison of different routes of administration of 400 micro gram misoprostol</description>
        </group>
        <group group_id="E2">
          <title>Rectal &amp; Sublingual Placebo</title>
          <description>will receive rectal placebo&quot;2 tablets” and sublingual placebo&quot;2 tablets”.</description>
        </group>
        <group group_id="E3">
          <title>Rectal Misoprostol &amp; Sublingual Placebo</title>
          <description>will receive 400 microgram of misoprostol (Sigma) rectal &quot;2 tablets&quot; and sublingual placebo&quot;2 tablets&quot;.
Misoprostol: Comparison of different routes of administration of 400 micro gram misoprostol</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>wound sepsis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Mohamed S. Sweed, Dr.Mourad M.El-Said, Dr.Amgad E. Abou-Gamrah, Dr.Mohamed M. Abd-El-Hamid</name_or_title>
      <organization>AinShams University</organization>
      <phone>01001222047 ext +2</phone>
      <email>drmsweed@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

